Phase II Study of Maintenance With Azacitidine in MDS Patients Achieving Complete or Partial Remission (CR or PR) After Intensive Chemotherapy.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Azacitidine (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 19 Jan 2012 Biomarkers information updated
- 08 Feb 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 04 May 2007 New trial record.